Effect of Empagliflozin in Prediabetes

A comparative analysis of effects of empagliflozin whit metformin on cardiometabolic factors and blood glucose of prediabetic patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220902055858N1

Enrollment

Registered

2022-09-24

Start date

2022-09-23

Completion date

Unknown

Last updated

2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Impaired fasting glucose. Condition 2: Impaired glucose tolerance. Impaired fasting glucose Impaired glucose tolerance (oral)

Interventions

Intervention 1: Intervention group: Prediabetic patients receiving metformin 500 mg twice a day ABIDI.Co for 3 months. Intervention 2: Intervention group: Prediabetic patients receiving empagliflozin

Eligibility

Sex/Gender

All

Age

17 Years to 65 Years

Inclusion criteria

Inclusion criteria: Prediabetic Patient Age 17 to 65 years Not receiving blood sugar-lowering drugs

Exclusion criteria

Exclusion criteria: Known case of Diabetes A history of urinary tract infection

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: Measurement of fasting blood sugar at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Postprandial blood sugar. Timepoint: Measurement of Postprandial blood sugar at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Glycosylated hemoglobin. Timepoint: Measurement of Glycosylated hemoglobin at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Uric Acid level. Timepoint: Measurement of Uric Acid at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;C-Reactive Protein (CRP). Timepoint: Measurement of CRP at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Cholesterol. Timepoint: Measurement of cholesterol at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Low Density Lipoprotein (LDL). Timepoint: Measurement of LDL at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;High Density Lipoprotein (HDL). Timepoint: Measurement of HDL at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Fasting Insulin Level. Timepoint: Measurement of Fasting Insulin Level at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.	—

Measure

Time frame

Fasting blood sugar. Timepoint: Measurement of fasting blood sugar at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Postprandial blood sugar. Timepoint: Measurement of Postprandial blood sugar at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Glycosylated hemoglobin. Timepoint: Measurement of Glycosylated hemoglobin at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Uric Acid level. Timepoint: Measurement of Uric Acid at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;C-Reactive Protein (CRP). Timepoint: Measurement of CRP at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Cholesterol. Timepoint: Measurement of cholesterol at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Low Density Lipoprotein (LDL). Timepoint: Measurement of LDL at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;High Density Lipoprotein (HDL). Timepoint: Measurement of HDL at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.;Fasting Insulin Level. Timepoint: Measurement of Fasting Insulin Level at the beginning of the study and 12 weeks after the start of the intervention. Method of measurement: Peripheral blood biochemistry sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmin Moosavi

Shahre-kord University of Medical Sciences

amin.moosavi@skums.ac.ir+98 38 3365 8225

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026